White Matter Brain Changes In Post-Chemotherapy Breast Cancer Patients Overview In this study, the objective was to evaluate white matter microstructural changes in older breast cancer survivors 5-15 years post-chemotherapy treatment. The participants included breast cancer survivors aged 65 or older who underwent chemotherapy (C+) and those who did not (C-), along
Tag: chemotherapy
NSCLC First Line Therapy Chemotherapy Combinations
NSCLC First Line Therapy Chemotherapy Combinations Overview This retrospective study explores optimal first-line treatments for non-small cell lung cancer (NSCLC) patients with brain metastases (BMs) lacking driver gene alterations. The research compares the effectiveness of immunotherapy plus chemotherapy (ICI+Chemo) against bevacizumab plus chemotherapy (Beva+Chemo). The study, conducted between March 2017 and May
Gastric Xanthoma And Gastric Cancer Risk
Gastric Xanthoma And Gastric Cancer Risk Gastric cancer stands as a formidable global threat, ranking among the top cancers in incidence and mortality. Amidst known risk factors like dietary habits and infections, a lesser-known player, gastric xanthoma (GX), emerges as a potential link to this complex puzzle. This study delves into
Cabozantinib Therapy In Hepatocellular Carcinoma
Cabozantinib Therapy In Hepatocellular Carcinoma Hepatocellular carcinoma (HCC) is a predominant form of liver cancer, accounting for approximately 90% of cases. Unfortunately, it carries a grim prognosis, with a median survival rate ranging from 6 to 18 months. Historically, sorafenib had been the established first-line therapy for HCC. However, in recent
PD-1/L1 Inhibitors: Treatment Efficacy In Urothelial Carcinoma
PD-1/L1 Inhibitors: Treatment Efficacy In Urothelial Carcinoma Overview Programmed cell death‐1/ligand 1 (PD-1/PD-L1) inhibitors represent a novel therapeutic approach for advanced urothelial carcinoma, prompting the need for a comparative assessment of their effectiveness and safety in comparison to traditional chemotherapy. To address this, a comprehensive meta-analysis of randomized controlled trials conducted until
Ibrutinib Treatment In Waldenström Macroglobulinemia
Ibrutinib Treatment In Waldenström Macroglobulinemia Waldenström macroglobulinemia (WM) is a rare type of non-hogdkins lymphoma driven by the gene mutation MYD88L265P. Ibrutinib, the first approved treatment, is effective but can cause side effects. A study found that 27% of WM patients needed to reduce Ibrutinib doses due to side effects like
Chemotherapy-Induced Thrombocytopenia in Nasopharyngeal Carcinoma
Chemotherapy-Induced Thrombocytopenia in Nasopharyngeal Carcinoma Overview This study aimed to investigate serious chemotherapy-induced thrombocytopenia (CIT) in nasopharyngeal carcinoma (NPC), focusing on its incidence, consequences, and predictors. The retrospective analysis of NPC patients from 2013 to 2015 revealed a 5.21% incidence of serious chemotherapy-induced thrombocytopenia. Patients experiencing severe thrombocytopenia had notably worse long-term prognoses,
Uterine Leiomyosarcoma: A Meta-Analysis Of Systemic Therapy Effectiveness
Uterine Leiomyosarcoma: Systemic Therapy Effectiveness Overview Uterine leiomyosarcoma (uLMS) is an aggressive type of mesenchymal tumor linked to a bleak prognosis. The primary treatment for advanced uLMS is systemic chemotherapy, although the most effective regimen remains uncertain. To address this, we conducted an extensive analysis, including both meta-analysis and metaregression, aiming to
Hearing Screening After Chemotherapy: A Study On Childhood Cancer Survivors
Hearing Screening After Chemotherapy: A Study On Childhood Cancer Survivors The Study Background The survival rates of children with cancer have increased steadily since the mid-1970s, from 58% to 85% in developed countries. However, these improvements are tainted by immediate and late effects of treatment. Geenen et al. and Oeffinger et al.
Monotherapy Or Chemotherapy Adjunct: Pembrolizumab In Advanced NSCLC
Monotherapy Or Chemotherapy Adjunct: Pembrolizumab In Advanced NSCLC Objectives To assess the effectiveness and safety of pembrolizumab monotherapy and in combination with chemotherapy in patients with advanced non–small-cell lung cancer (NSCLC). Introduction Historically, patients with advanced NSCLC have a poor prognosis despite the use of platinum-based chemotherapy drugs. The 5-year relative survival rate of
